市場調查報告書
商品編碼
1159353
卵巢癌症治療藥的全球市場(2022年~2028年)Ovarian Cancer Drugs Market 2022-2028 |
全球卵巢癌症治療藥的市場規模,在預測期間內預計以13.8%大幅度的年複合成長率成長。卵巢癌症治療的認識高漲,和新興國家的醫療費增加,推動卵巢癌症治療藥市場成長。醫療費增加,使許多人能利用先進的醫療設施,進而推動含卵巢癌症的各種癌症的診斷和治療。
本報告提供全球卵巢癌症治療藥市場相關調查,市場概要,以及競爭情形,各市場區隔的市場,各地區分析,及企業簡介等資訊。
Global Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report by Drug Class (PARP Inhibitors, Angiogenesis Inhibitors, PD-L1 Inhibitors), and by Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, and Others) Forecast Period (2022-2028)
The global ovarian cancer drugs market is anticipated to grow at a substantial CAGR of 13.8% during the forecast period. The rising awareness towards the ovarian cancer treatment along with increase in healthcare expenditure in emerging economies is propelling the growth of ovarian cancer drugs market. The increase in expenditure on healthcare is mainly supported by the need among individuals for quality healthcare services. According to the statistics by the World Bank, the current health expenditure (% of GDP) around the world increased from 8.63% in 2000 to 9.84% in 2019. Rising healthcare expenditure is allowing a large number of people to access advanced healthcare facilities, which in turn, is contributing to the diagnosis and treatment of various cancers, including ovarian cancer.
The global Ovarian Cancer Drugs market is segmented based on the drug class, and therapy. Based on the drug class, the market is segmented into PARP inhibitors, angiogenesis inhibitors, and PD-L1 inhibitors. Based on, the therapy the market is sub-segmented into the chemotherapy, targeted therapy, immunotherapy, and others. The above-mentioned segments can be customized as per the requirements. On the basis of drug class, PARP inhibitors are anticipated to be the fastest growing drug class in the ovarian cancer market owing to increasing research and development among major key players to develop new products is anticipated to drive the growth of the market. For instance, in April 2020, the US Food and Drug Administration (FDA) approved the company's supplemental New Drug Application (sNDA) for Zejula (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, as a monotherapy maintenance treatment for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Furthermore, other factors such as increase in demand for PARP inhibitors due to their superior efficacy are likely to boost further market growth.
Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Asia-Pacific is estimated to contribute significantly to the growth of the market. China and India are the major contributors to the growth of the Asia-Pacific ovarian cancer drugs market. The high prevalence and incidence rate of ovarian cancer in China, augments the adoption of drugs and devices for the treatment of ovarian cancer, marking it one of the key factors that drive the market growth. The rising healthcare industry and cancer research institutes along with increasing awareness regarding the treatment procedures of ovarian cancer is further propelling market growth. Additionally, Asia-Pacific comprises approximately 60% of the world population, the region accounts to register a significant proportion in total cases of cancer every year, owing to which, the market for ovarian cancer drugs is growing proportionally in Asia-Pacific.
The major companies serving the global Ovarian Cancer Drugs market include AstraZeneca PLC, Clovis Oncology, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co., Inc. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, In 2020, AstraZeneca and MSD Inc announced that Lynparza*(Olaparib) in combination with bevacizumab has been approved in the US for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
Research Methodology
The market study of the global ovarian cancer drugs market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include:
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers: